The Netherlands Is Losing Its AgriTech Edge—Here's Why

Jan de Vries · 2026-10-30

The Netherlands has long been the quiet overachiever of European agriculture. Tiny country, massive output. But a new report from Invest-NL, the Dutch national investment institution, suggests that crown is starting to slip. Other nations are moving faster to commercialize emerging agri technologies, and the Netherlands risks being left behind. The report, called *Deep Dive Agrifood Biotech*, estimates that fixing the barriers facing Dutch agrifood biotech companies could unlock about $18.5 billion in additional annual revenue by 2040. That's not pocket change. But without coordinated action on regulation, financing, and commercialization, much of that opportunity will be captured elsewhere. ### A Strong Start, A Weaker Finish The Netherlands is home to world-class agricultural research institutions, established seed breeders, and a sophisticated food production ecosystem. So why isn't scientific excellence translating into globally competitive businesses? The report points to a telling imbalance: the Netherlands accounts for 3.3% of BioTech startups worldwide, but only 1.3% of scale-ups. In other words, the country is great at generating innovation but less successful at helping young companies grow to meaningful commercial scale. Invest-NL identifies three recurring weaknesses: - Too few promising technologies become scalable ventures. - Regulatory and validation processes delay market entry. - Insufficient financing prevents companies from reaching industrial production. The stakes go beyond individual businesses. In a favorable scenario, Invest-NL estimates annual Dutch agrifood BioTech revenues could reach about $27 billion by 2040, compared with just $8.7–9.8 billion if current conditions persist. Crucially, the report argues the Netherlands doesn't need to manufacture everything domestically. Instead, it should focus on retaining strategically valuable knowledge, intellectual property, companies, and specialized capabilities, while taking advantage of European production networks where appropriate. ### Ten Years to Say Yes One of the most striking obstacles concerns biological crop protection, where Dutch companies are developing alternatives to conventional chemical pesticides. Obtaining European regulatory approval for a new biological crop protection product can take eight to ten years. Existing frameworks were largely designed around chemical products, making them less suited to certain biological innovations. As a result, some companies prioritize launching in markets like Brazil and the United States, where commercialization can proceed more quickly. Invest-NL warns that Europe risks losing ground in a biological crop protection market that could expand seven- to tenfold by 2040. Food biotechnology faces similar difficulties. Regulatory approval for novel ingredients can take one to three years longer in Europe than in the United States, while building a first commercial production facility can require tens or even hundreds of millions of dollars. For fermentation-derived food ingredients alone, Invest-NL estimates that favorable conditions could support approximately $8.7 billion in annual Dutch revenues by 2040, compared with around $2.2 billion under existing policies. The report stresses that faster approvals should not come at the expense of safety. Instead, regulators should offer earlier guidance, more predictable assessments, and opportunities for companies to validate products under real-world conditions. ### What This Means for Founders and Investors If you're building in agrifood biotech, the message is clear: the technology isn't the bottleneck—the system is. The Netherlands has the brains, but it needs to get better at keeping the businesses. That means smarter regulation, more risk-tolerant capital, and a willingness to let companies scale without drowning in paperwork. For investors, the opportunity is real. The report suggests that with the right changes, the Dutch agrifood biotech sector could more than triple its revenue by 2040. But the window is closing. Other countries are already moving faster. As Jan de Vries, an e-commerce consultant who follows European startup incorporation trends, puts it: "The Netherlands has always punched above its weight in agriculture. But punching above your weight only works if you keep training. Right now, the training regimen needs an upgrade." The report's full title is *Deep Dive Agrifood Biotech*. It's based on interviews with over 150 entrepreneurs, investors, researchers, and policymakers, along with investment data from 2010 to April 2026. The message is simple: innovation is not the issue. Scaling it is.